Mr. Chris Dallin reports

ASEP MEDICAL ANNOUNCES PROPOSED SHARE CONSOLIDATION

Subject to regulatory approval, Asep Medical Holdings Inc.'s board has resolved to consolidate the company's issued and outstanding common shares on a one postconsolidation common share for every 10 preconsolidation common shares. All fractional common shares resulting from the consolidation will be rounded to the nearest 0.5, and no cash will be paid in lieu of fractional postconsolidation common shares. All outstanding stock options and share purchase warrants of the company will also be adjusted by the consolidation ratio, and the respective exercise prices of outstanding options and share purchase warrants will be adjusted accordingly. The consolidation is subject to approval by the Canadian Securities Exchange. The company's name and trading symbols will remain unchanged.

If the consolidation is accepted by the exchange, the company's shares will commence trading on a postconsolidated basis on April 16, 2025. Shareholders that hold common shares in the company through the direct registration system will not receive a letter of transmittal in connection with the consolidation. For shareholders who hold certificates for the common shares they hold in the company will receive a letter of transmittal, which will be sent by mail to registered shareholders advising that the consolidation has taken effect and instructing registered shareholders to take action to exchange their share certificates. The letter of transmittal will contain instructions on how registered shareholders can exchange their share certificates. Beneficial shareholders who hold their shares through a broker or other intermediary and do not have shares registered in their own names will not be required to take any action to exchange their share certificates.

About Asep Medical Holdings Inc.

Asep Medical Holdings is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine. The company is a consolidation of three existing private companies, all with technology in advanced development -- Sepset Biosciences Inc. (proprietary diagnostic tools to enable the early and timely identification of sepsis), ABT Innovations Inc. (broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections) and SafeCoat Medical Inc. (an antibacterial peptide medical device coating technology).

Sepset Biosciences Inc. is in the final stages of preparation for clinical studies and commercialization of an in vitro diagnostic test that involves a patient gene expression signature that helps assess the development of severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary initial treatment for sepsis. Sepsis was responsible for nearly 20 per cent of all deaths on the planet in 2017 and essentially all deaths due to COVID-19 and other pandemics. The SepsetER test is a blood-based gene expression assay that is straightforward to implement, and results are obtained about an hour after taking a blood sample in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests, enabling the risk assessment for progression to severe sepsis within approximately 60 minutes of initiating the test. Bacterial culture, the gold standard, provides results after approximately 15 hours but can be as long as three. Asep believes its test will enable critical early decisions to be made by physicians regarding appropriate therapies and thus reduce overall morbidity and mortality due to sepsis.

ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections (such as dental, wound, sinusitis, skin, medical device infections, chronic infections, lung, bladder, ear-nose and throat, and orthopaedic), anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. The company is in the preclinical development phase with promising data for the first three indications.

SafeCoat Medical Inc.'s technology encompasses anti-fouling self-assembling polymers combined with conjugated antimicrobial peptides, which can be applied to various surfaces as antimicrobial and anti-fouling coatings. In particular, the invention relates to coatings that may be applied to multiple medical devices and implants, and feasibility has been demonstrated in animal models. The company's expertise also encompasses the methods for manufacturing and applying these anti-bacterial coatings.

We seek Safe Harbor.